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Background: EGFR, a receptor tyrosine kinase (RTK), is frequently overexpressed and mutated in non-small cell lung
cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have been widely used in the treatment of many cancers, including
NSCLC. However, intrinsic and acquired resistance to TKI remains a common obstacle. One strategy that may help
overcome EGFR-TKI resistance is to target EGFR for degradation. As EGFR is a client protein of heat-shock protein 90
(HSP90) and sulforaphane is known to functionally regulate HSP90, we hypothesized that sulforaphane could
attenuate EGFR-related signaling and potentially be used to treat NSCLC.
Results: Our study revealed that sulforaphane displayed antitumor activity against NSCLC cells both in vitro and in vivo.
The sensitivity of NSCLC cells to sulforaphane appeared to positively correlate with the inhibition of EGFR-related
signaling, which was attributed to the increased proteasomal degradation of EGFR. Combined treatment of
NSCLC cells with sulforaphane plus another HSP90 inhibitor (17-AAG) enhanced the inhibition of EGFR-related
signaling both in vitro and in vivo.
Conclusions: We have shown that sulforaphane is a novel inhibitory modulator of EGFR expression and is
effective in inhibiting the tumor growth of EGFR-TKI-resistant NSCLC cells. Our findings suggest that sulforaphane
should be further explored for its potential clinical applications against NSCLC.
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Lung cancer is the most common cause of cancer deaths
worldwide, and non-small cell lung cancer (NSCLC) is
the major dominant cell type [1]. The epidermal growth
factor receptor (EGFR) is highly expressed in many hu-
man tumors, including NSCLC. The intracellular signal-
ing pathways activated by EGFR, which include the
PI3K/AKT/mTOR, RAS/RAF/MAPK and JAK/STAT
pathways, play central roles in controlling cell survival,
growth and proliferation [2]. Inhibition of EGFR signal-
ing, therefore, has been widely explored for its thera-
peutic potential against many different cancers [3].
Treatment with EGFR-tyrosine kinase inhibitor (TKI)
has led to dramatic clinical improvement in some pa-
tients with NSCLC [4], but intrinsic and acquired resist-
ance to EGFR-TKI is common [5,6]. One potential
strategy for addressing EGFR-TKI resistance is to target* Correspondence: tcvwg@mail.cgu.edu.tw
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unless otherwise stated.EGFR for degradation. As receptor tyrosine kinases
(RTKs) comprise the largest category of heat shock pro-
tein 90 (HSP90) client proteins [7], one strategy aimed at
targeting RTKs for degradation is to inhibit HSP90. Many
inhibitors of HSP90 have been developed and some of
them, such as 17-N-allylamino-17-demethoxygeldanamy-
cin (17-AAG), are currently undergoing clinical trials as
potential anticancer drugs [8]. However, 17-AAG is poorly
soluble and suffers from low oral bioavailability, metabol-
ism issues and hepatotoxicity [8].
Natural products have been the major source of the
currently available anticancer drugs, and identifying their
active chemical ingredients and deducing the molecular
targets of such ingredients is viewed as an attractive ap-
proach for drug development. Sulforaphane, which was
first identified in broccoli sprouts and is present at high
concentrations in most cruciferous vegetables [9], has
been shown to be potentially effective at moderating
multiple cellular targets involved in cancer development,
leading to the repression of cancer cell proliferation,
stimulation of cancer cell apoptosis, and inhibition ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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treatment with doxorubicin and sulforaphane has been
shown to reverse the doxorubicin-resistant phenotype in
mutant mouse fibroblasts [12], while combined treat-
ment with epigallocatechin gallate (EGCG) and sulfo-
raphane has been shown to induce apoptosis in
paclitaxel-resistant ovarian cancer cell lines [13]. There-
fore, sulforaphane appears to effectively counteract the
drug-resistant phenotypes of several cancers. In view of
the recent finding that sulforaphane can inhibit HSP90
function in prostate and pancreatic cancer cell lines
[14-16], we hypothesized that sulforaphane may be a
novel EGFR-targeting therapeutic agent that could be
used for the treatment of NSCLC. In this study, we ex-
amined the EGFR modulation activity and antitumor po-
tential of sulforaphane in several NSCLC cell lines
which harboring wild-type or mutant EGFR. Our results
indicate that sulforaphane is a novel modulator of EGFR
and is effective in inhibiting the tumor growth of EGFR-
TKI-resistant NSCLC cells.Methods
Cell lines and culture
The NSCLC-derived cell lines, A549, H1975 and H3255,
were obtained from the American Type Culture Collec-
tion (Manassas, VA, USA). PC9/gef was a gefitinib-
resistant cell line that had been selected from parental
PC9 cells by continuous exposure to an increasing dos-
age of gefitinib over ~ six months, as previously de-
scribed [17]. The human NSCLC cell line, CL1-5, was as
described previously [18]. A549 and CL1-5 cells express
wild-type EGFR; PC9 cells contain a deletion in exon 19
of EGFR; and H1975 and H3255 cells harbor two muta-
tions (L858R and T790M) and a single mutation
(L858R), respectively, in EGFR. The primary normal hu-
man fibroblasts (HFB) were kindly provided by Dr. Pan-
Chyr Yang (National Taiwan University, Taipei, Taiwan).
All cells were cultivated in RPMI-1640 medium contain-
ing 10% fetal bovine serum (FBS), 2 mM sodium pyru-
vate, 100 U/ml penicillin and 100 U/ml streptomycin.
Cells were grown at 37°C in a humidified incubator con-
taining 5% CO2.Antibodies, oligonucleotides, and reagents
Culture media, chemical compounds and FBS were
purchased from Life Technologies (Grand Island, NY,
USA). Antibodies against phospho-EGFR (Tyr1068),
phospho-STAT3 (Tyr705) and phospho-AKT (Ser473)
were purchased from Cell Signaling (Temecula, CA,
USA). Antibodies against EGFR, STAT, AKT and β-
actin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Sulforaphane, MG132 and cy-
cloheximide were purchased from Sigma (St. Louis,MO, USA). 17-AAG was purchased from Calbiochem
(Gibbstown, NJ, USA).Cell viability, synergy and Western blot analyses
Cell viability (MTT) assays, synergy and Western blot-
ting were performed as described previously [19,20].Foci formation assay
Cells were plated to 6-well plates (100 cells per well)
for 24 h and then treated with sulforaphane at the indi-
cated concentrations for 6 days in complete culture
medium. The treated cells were incubated in complete
medium without sulforaphane for an additional 8 days,
and then subjected to staining with 0.001% crystal vio-
let. A foci was defined as a group of stained cells >
1 mm in diameter.Stability of EGFR analysis
Cells were treated with or without 10 μM sulforaphane
for 12 h. Cells were then treated with cycloheximide
(40 μg/ml) for 0, 2, 4, 6, and 8 h and the level of total
EGFR (tEGFR) was determined by Western blotting.Subcutaneous xenograft-based animal studies
The in vivo antitumor activity of sulforaphane and/or
17-AAG against human NSCLC was studied using 6-
week-old nude BALB/c nu/nu male mice (n = 6 per
group). Animals were inoculated subcutaneously in the
right flank with tumor cells (2 × 106) in a volume of
100 μL on day 0. Mice were randomly divided into four
groups on day 5 and treated with PBS as control,
10 μmol/kg sulforaphane, 25 mg/kg 17-AAG, or both
sulforaphane and 17-AAG [15]. Sulforaphane was dis-
solved in PBS whereas 17-AAG was dissolved in 10%
DMSO, 70% cremophor/ethanol (3:1), and 20% PBS
[15]. Sulforphane was injected intratumorally five times
per week. 17-AAG was administered intraperitoneally
three times per week. Tumors were generally palpable at
5 days after inoculation. Drug treatment began at Day 5
and tumor volumes were measured (using a caliper and
calculated as length x width2 × 0.5) twice weekly until
21 days after injection [21]. All animal experiments were
performed in accordance with the guidelines for the
Animal Care Ethics Commission of Chang Gung Univer-
sity under an approved animal protocol.Statistical analysis
The presented results are representative of three inde-
pendent experiments with similar results. Statistical dif-
ferences were evaluated using the Student’s t-test, and








































































































































































Fig. 1 (See legend on next page.)
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Fig. 1 Effects of sulforaphane on the cell viability and clonogenic ability of NSCLC cells. (a) Time- and concentration-dependent inhibition of NSCLC
cell viability by sulforaphane (SFN). Cells were treated with various concentrations of sulforaphane for 24 h (upper panel), 48 h (middle panel) and 72 h
(lower panel), and cell viability was evaluated by MTT assay. (b) Inhibition of the clonogenic ability of NSCLC cells by sulforaphane. H1975 (upper panel),
PC9/gef (middle panel) and A549 (lower panel) cells were treated with various concentrations of sulforaphane for 6 days and cultured for an additional
8 days in the absence of sulforaphane. The numbers of foci were scored, and the data are presented as relative foci-forming ability (FFA). Data are
expressed as mean ± SD of three independent experiments. *p < 0.05; **p < 0.01; and ***p < 0.001, as analyzed with the unpaired t-test
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Effects of sulforaphane on the viability and growth of
human NSCLC cells in vitro
To evaluate the antitumor effects of sulforaphane on
NSCLC cells, the TKI-resistant (PC9/gef, H1975, A549,
and CL1-5) and the TKI-sensitive (H3255) cells were
treated with sulforaphane at 5–20 μM and their viability
were measured by MTT assay. As shown in Fig. 1a, sul-
foraphane treatment remarkably reduced the viability of
human NSCLC cells in a time- and concentration-
dependent manner. Among the TKI-sensitive (H3255)
and TKI-resistant (PC9/gef, H1975, A549, and CL1-5)
NSCLC cells, H1975 cells exhibited the highest sensitiv-
ity to sulforaphane (Table 1 and Fig.1a). A primary nor-
mal human fibroblasts (HFB), on the other hand, were
rather resistant to sulforaphane (Table 1). Next, we ex-
amined the effect of sulforaphane on the foci-forming
ability of TKI-resistant (PC9/gef, H1975, and A549)
NSCLC cells. As shown in Fig. 1b, the foci-forming abil-
ity of H1975 and PC9/gef cells was fully suppressed by
sulforaphane at a concentration of 8 μM (Fig. 1b, upper
and middle panels). In contrast, a much higher concen-
trations of sulforaphane (e.g., 30 μM) were required to
produce the same inhibition of foci-forming ability in
A549 cells (Fig. 1b, lower panel).Table 1 The IC50 of sulforaphane for human NSCLC cells






A549 Wild-type 10.2 ± 0.15
CL1-5 Wild-type 9.7 ± 0.33
H3255 L858R b 14.5 ± 0.21
PC9/gef c Exon 19 del. 7.3 ± 0.25
H1975 L858R/T790M d 5.9 ± 0.18
HFB Wild-type 65.4 ± 0.29
aCells were treated with various concentrations of sulforaphane for 48 h, and
cell viability was determined by MTT assay. The IC50 values were calculated by
non-linear regression analysis. Values are given as means ± standard deviation
bL858R substitution in exon 21
cPC9/gef is a gefitinib-resistant cell line that was selected from parental PC9
cells (which contain a deletion in exon 19 of EGFR) by continuous exposure to
increasing doses of gefitinib over ~ 6 months













Fig. 2 Effects of sulforaphane on EGFR-related signaling in NSCLC
cells. H1975, PC9/gef (a), H3255 (b) and A549 (c) cells were treated
with various concentrations of sulforaphane (SFN) for 24 h, and the
levels of total (t) and phosphoylated (p) proteins in the cell lysates
were determined by Western blotting. β-actin was used as the
loading control. The data shown are representative of three
experiments with similar results
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Fig. 3 Effects of sulforaphane and MG132 on the stability of EGFR in NSCLC cells. (a) Cells were treated with or without 10 μM sulforaphane for
the indicated durations in the presence of 40 μg/ml cycloheximide, and the level of tEGFR was determined by Western blotting. β-actin was used
as the loading control. The relative levels of tEGFR at different times were quantified by densitometer and were shown below tEGFR. (b) H1975
cells were treated with 10 μM sulforaphane for 24 h in the presence or absence (control) of 10 μM MG132. The levels of tEGFR were assessed by
Western blotting. β-actin was used as the loading control. The relative levels of tEGFR were quantified and shown below tEGFR. The data shown
are representative of three experiments with similar results
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signaling in NSCLC cell lines
Mutant EGFRs induce oncogenic effects by triggering
downstream signaling and anti-apoptotic pathways,
most markedly those modulated by signal transducer
and activator of transcription (STAT) proteins and Akt
[22]. Because sulforaphane appeared to exhibit a greater
anti-proliferative effect in TKI-resistant NSCLC cells
harboring mutant EGFR (H1975 and PC9/gef ) than
wild-type EGFR (A549) (Fig. 1 and Table 1), we hypoth-
esized that suforaphane might interfere with the EGFR
signaling. To test this postulate, we treated H1975 and
PC9/gef cells with sulforaphane (0 – 20 μM) and exam-
ined EGFR-related signaling. As shown in Fig. 2, the ac-
tivation of phospho-EGFR (pEGFR) and phospho-Akt
(pAkt) were readily detected in untreated H1975 and
PC9/gef cells, and were greatly reduced after treatment
with sulforaphane. Furthermore, the phospho-STAT3
(pSTAT3) was also greatly reduced in sulforaphane-
treated H1975 cells but not in sulforaphane-treated
PC9/gef cells. The levels of p-EGFR, p-STAT3, and p-
Akt were slightly reduced in sulforaphane-treated
H3255 cells (Fig. 2b). In A549 cells, we were not able to
detect pEGFR, pAkt or pSTAT3 in the untreated cells,
and thus could not address the effect of sulforaphane
on EGFR-related signaling in the absence of any stimu-
lation. Nonetheless, the levels of total EGFR (tEGFR)
were also reduced upon treatment with sulforaphane in
A549 cells (Fig. 2c). Notably, however, tEGFR was more
dramatically reduced in H1975 and PC9/gef cells com-
pared to H3255 and A549 cells following sulforaphane
treatment (Fig. 2).
Sulforaphane potentially modulates EGFR expression by
accelerating protein degradation in NSCLC cells
As sulforaphane is a known proteasome activator [23],
we next tested whether this agent could regulate EGFR-
dependent signaling by affecting the stability of EGFR.
Cells (H1975, PC9/gef, H3255 and A549) were treated
with sulforaphane, protein synthesis was blocked by cy-
cloheximide treatment, and the stability of EGFR was
analyzed. As shown in Fig. 3a, the half-life of tEGFR in
the absence of sulforaphane treatment was about 7.5 h
in H1975 cells. In the presence of sulforaphane, the sta-
bility of EGFR was greatly reduced in H1975 and PC9/
gef cells but only slightly reduced in H3255 and A549cells. To address that the reduction of total EGFR
(tEGFR) by sulforaphane was mediated through the pro-
teasome, we examined the effects of a proteasome in-
hibitor (MG132) on the stability of EGFR in H1975 cells.
As shown in Fig. 3b, the level of tEGFR in sulforaphane-
treated cells was restored to about 80% when co-treated
with MG132. Collectively, these results demonstrate that
sulforaphane can stimulate the proteasome, thereby ac-
celerating the degradation of EGFR in NSCLC cells.
Sulforaphane enhances the antitumor activity of 17-AAG
in NSCLC cells in vitro and in vivo
Heat shock protein 90 (HSP90) inhibitors reportedly have
antitumor effects on TKI-resistant NSCLC cells harboring
the T790M mutation in EGFR [24,25]. Our finding that
sulforaphane enhances the degradation of EGFR (Fig. 2)
prompted us to speculate that sulforaphane might prove
useful as a single agent or as part of a combination ther-
apy for the treatment of NSCLC harboring the EGFR
T790M mutation. To test this hypothesis, we examined
the efficacy of sulforaphane plus 17-AAG against H1975
cells in vitro and in vivo. To evaluate the antitumor effect
of the combined treatment in vitro, we chose to use a sub-
optimal concentration of sulforaphane (4 μM) that had lit-
tle or no effect on EGFR-related signaling (see Fig. 2). As
shown in Fig. 4a, treatment of H1975 cells with 17-AAG
alone dose-dependently reduced the levels of tEGFR and
pEGFR. In the presence of 4 μM sulforaphane, treatment
of H1975 cells with 17-AAG triggered much greater re-
ductions in the levels of tEGFR and pEGFR. Similarly, the
presence of 4 μM sulforaphane enhanced the cell-killing
effect of 17-AAG, as assayed by the MTT method (Fig. 4b).
These results indicate that combined treatment of
17-AAG plus sulforaphane appears to exert a synergistic
effect (combination index < 1) on the cell viability and
EGFR degradation of H1975 cells in vitro.
To investigate the antitumor effects of the combined
treatment in vivo, we employed a xenograft animal
model. Nude mice injected with H1975 cells developed
tumors that reached ~ 100 mm3 in size after about
5 days. Beginning on day 5, the mice were treated with
PBS, 25 mg/kg 17-AAG, 10 μmol/kg sulforaphane, or a
combination of sulforaphane and 17-AAG. Sulforphane
was injected intratumorally five times per week. 17-AAG
was administered intraperitoneally three times per week.
As shown in Fig. 4c, tumor growth was inhibited by the
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Fig. 4 (See legend on next page.)
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Fig. 4 Effects of sulforaphane plus 17-AAG on tumor cell activity in vitro and in vivo. (a and b) H1975 cells were treated with the indicated
concentrations of 17-AAG in the presence or absence of 4 μM sulforaphane for 24 h. The levels of total (t) and phosphoylated (p) EGFR were
assessed by Western blotting (a), and the viability of the treated cells was assessed by the MTT assay (b). The data shown are representative of
three experiments with similar results. (c and d) The effect of sulforaphane and 17-AAG treatment on subcutaneous xenografts of H1975 cells
in vivo. H1975 cells were injected subcutaneously into the flanks of nude mice (n = 6 per group). Five days later (arrow), the mice were injected
with PBS, 25 mg/kg 17-AAG, 10 μmol/kg sulforaphane, or a combination of sulforaphane and 17-AAG. Sulforphane was injected intratumorally
five times per week. 17-AAG was administered intraperitoneally three times per week. Tumor volumes were determined twice weekly. The
average tumors volumes (c) and body weights (d) were determined for each group. Results shown are the means ± SD of six mice; *p < 0.05;
and **p < 0.01, as analyzed with the unpaired t-test
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the combined treatment with sulforaphane plus 17-AAG
produced an even greater inhibition of tumor growth.
Under our experimental conditions, there was no notice-
able change in body weight or overt sign of toxicity in
the treated mice (Fig. 4d).
Discussion
The receptor tyrosine kinase (RTK), EGFR, is a trans-
membrane protein with cytoplasmic kinase activity that
transduces important growth factor signaling from the
extracellular milieu to the cell. EGFR is frequently over-
expressed and mutated in NSCLC [26]. Since many mu-
tant EGFRs can activate signal transduction independent
of ligand binding, EGFR mutations are strong predictors
for the efficacy of EGFR-TK inhibitor (TKI)-based thera-
peutics. However, intrinsic and acquired resistance to
EGFR-TKI remains a common phenomenon. To over-
come the problems associated with EGFR-TKI resist-
ance, strategies aimed at inhibiting EGFR signaling have
been explored. As RTKs comprise the largest category of
client proteins for HSP90 [7], one strategy aimed at tar-
geting RTKs for degradation is to inhibit HSP90.
In view of the recent finding that sulforaphane can
functionally regulate HSP90 [14-16], we postulated that
this agent might attenuate EGFR signaling, and thus
could prove useful for the treatment of TKI-resistant
NSCLC. Here, we demonstrate that treatment with sul-
foraphane reduced viability and inhibited foci formation
of TKI-resistant (H1975, PC9/gef, A549 and CL1-5)
NSCLC cells (Fig. 1). H1975 cells, which harbor EGFR
double mutations (L858R and T790M), were the most
sensitive to sulforaphane treatment in vitro (Fig. 1). The
sensitivity of TKI-resistant NSCLC cells to sulforaphane
appears to be correlated with increased inhibition of
EGFR-related signaling in these cells (Fig. 2). Although
we do not yet know the detailed mechanisms underlying
this increased inhibition of EGFR-related signaling, we
found that sulforaphane appeared to decrease the stabil-
ity of EGFR, possibly by increasing its proteasomal deg-
radation (Fig. 3). In addition, we found that sulforaphane
enhanced the degradation of total EGFR and phosphor-
EGFR by 17-AAG (Fig. 4a). As 17-AAG is known to
interact with the N-terminal nucleotide-binding domainof HSP90 (8) to exert its inhibition activity, it remains to
be determined if sulforaphane may also interact with the
N-terminal nucleotide-binding domain of HSP90. Previous
studies have suggested that sulforaphane may inactivate
histone deacetylase 6 (HDAC6)-mediated deacetylation of
HSP90 [16], directly interact with specific amino acid resi-
dues of HSP90 and induce degradation of HSP90 client
proteins [14], and/or activate the proteasomal system [23].
It is likely that the sulforaphane-induced modulation of
EGFR stability observed herein may be attributed to one or
more of these mechanisms.
Our finding of a novel role for sulforaphane in modulat-
ing EGFR led us to speculate that this agent might be cap-
able of enhancing the therapeutic potential of other HSP
inhibitors, such as 17-AAG, in treating TKI-resistant
NSCLC. Indeed, we found that sulforaphane increased the
antitumor activity of 17-AAG against TKI-resistant
H1975 cells both in vitro and in vivo (Fig. 4). Therefore,
sulforaphane may have potential as a nontoxic additive
capable of increasing the therapeutic potential of other an-
ticancer agents to treat NSCLC.
Conclusions
In summary, we herein report that sulforaphane is a
novel modulator of EGFR that destabilizes EGFR and
down-regulates EGFR-related signaling in NSCLC cells.
It is suggested that sulfornaphane should be further ex-
plored for its potential therapeutic application in the
treatment of NSCLC.
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